SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On April 3, 2017, we awarded annual bonus options to purchase up
to 111,000 shares of our common stock to certain officers of the
Company as a reward for their services. The exercise price of the
options is based on the closing price of our common stock of
$7.06 on April 3, 2017, and the options vest in three equal
installments, beginning on April 3, 2018 and becoming fully
vested on April 3, 2020. Any unvested options will expire if the
employment of the respective executive terminates. The option
grants are as follows:
| Jim Schutz, Chief Executive Officer: 30,000 options; |
| Robert Miller, Chief Financial Officer: 30,000 options; |
|
Robert Northey, Executive Vice President of Research and Development: 17,000 options; |
|
Marc Umscheid, Chief Strategy and Marketing Officer: 17,000 options; |
|
Jeff Day, Presdident of Intraderm Pharmaceuticals division: 17,000 options. |
About SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA)
Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally. SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) Recent Trading Information
SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) closed its last trading session 00.00 at 6.86 with 20,059 shares trading hands.
